# Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease

> **NCT01602900** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** GSK356278
- **DRUG:** Rolipram

## Key facts

- **NCT ID:** NCT01602900
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-22
- **Primary completion:** 2012-04-12
- **Final completion:** 2012-04-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602900, "Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01602900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*